Atlas Trials

Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.

Clinical trial NCT04730895 · UNKNOWN

Trial details

NCT number
NCT04730895
Sponsor
Kafrelsheikh University
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Covid19 Vaccine
Start date
2021-07-01
Primary completion
2021-09-01
Enrollment
360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.